# Amber Bio

> Amber Bio is a biotechnology startup pioneering a new RNA writing platform that performs multi-kilobase edits, aiming to treat thousands of disease-causing mutations with a single product. Founded in 2021 by Jacob Borrajo and Basem Al-Shayeb out of the Broad Institute and UC Berkeley, the company launched in August 2023 with a $26M seed round co-led by Playground Global and Andreessen Horowitz Bio + Health.

- **Founded:** 2021
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Jacob Borrajo (Co-Founder & CEO), Basem Al-Shayeb (Co-Founder & CTO)
- **Team size:** ~22 employees
- **Products:** RNA Writing Platform, Single-Product Therapeutics
- **Notable:** Launched in August 2023 with an oversubscribed $26M seed round., Co-founders include a Doudna lab alum (Basem Al-Shayeb) and a Broad Institute alum (Jacob Borrajo)., Backed by both Playground Global and Andreessen Horowitz Bio + Health, with pharma participation from Eli Lilly.

## Products & services

- **RNA Writing Platform** — A multi-kilobase RNA editing platform built on novel Cas-based systems, designed to rewrite long stretches of RNA durably, safely, and reversibly.
- **Single-Product Therapeutics** — Therapeutic programs targeting diseases with high allelic diversity, where a single drug could treat thousands of distinct patient mutations.

## Achievements

- Launched in August 2023 with an oversubscribed $26M seed round.
- Co-founders include a Doudna lab alum (Basem Al-Shayeb) and a Broad Institute alum (Jacob Borrajo).
- Backed by both Playground Global and Andreessen Horowitz Bio + Health, with pharma participation from Eli Lilly.

## Latest updates

- **2023-08** — Amber Bio emerged from stealth with $26M seed financing co-led by Playground Global and a16z Bio + Health.

## Links

- Website: https://amber.bio
- LinkedIn: https://www.linkedin.com/company/amber-bio

---

Profile page: https://yespress.io/amber-bio
Published by YesPress — https://yespress.io
Last updated: 2026-06-29